The short version of Ion pairing fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-24 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
== See also == Phragmen's voting rules – a ballot load balancing method analogous to the idea of Archimedes' principle. Ship stability – Archimedes's theory of displacement of fluid is a core principle of ship stability. List of eponymous laws
The league's official statement concluded: "Reid strongly supports the AFL in its fundamental priority of looking after the health and welfare of players. He shares his concern over the serious circumstances which gave rise to the supplements saga at the Essendon Football Club ... The AFL accepts Dr Reid’s position and withdraws all charges against him, without penalty." Hird remained on the Essendon payroll and received his full salary during the suspension. The AFL initially demanded that the payments stopped when they were made public in December 2013 but acquiesced after determining that its legal position was weak. In Hird's absence, Mark Thompson stepped up to serve as senior coach in the 2014 season. At the time of the penalties for governance failures, no charges were laid against any players, whether or not banned substances had been used was unproven, and the ASADA and AFL investigation remained open.
Sympathomimetics (catecholaminergics)—e.g. amphetamine, methamphetamine, cocaine, methylphenidate, ephedrine, pseudoephedrine Entactogens (serotonergics, primarily phenethylamines)—e.g. MDMA (which is also an amphetamine) Eugeroics, e.g. modafinil Others arecoline (found in Areca catechu) caffeine (found in Coffea spp.) nicotine (found in Nicotiana spp.) rauwolscine (found in Rauvolfia serpentina) yohimbine (Procomil; a tryptamine alkaloid found in Pausinystalia johimbe)
A pulsed laser system facilitates the efficient coupling of a time-of-flight mass spectrometer (TOF-MS) to the resonance ionization set-up due to the instrument's abundance sensitivity. This is because TOF systems can produce an abundance sensitivity of up to 104 whereas magnetic mass spectrometers can only achieve up to 102. The total selectivity in a RIS process is a combination of the sensitivities in the various resonance transitions for multiple step-wise excitations. The probability of an atom to come in contact with the resonance of another atom is about 10−5. The addition of a mass spectrometer increases this figure by a factor of 106 such that the total elemental selectivity surpasses or at least compares to that of tandem mass spectrometry (MS/MS), the most selective technique available.
Sources: en.wikipedia.org
NH4CO2NH2 ⇌ CO(NH2)2 + H2O (ΔH = 15.5 kJ/mol at 160–180 °C (320–356 °F)) The overall conversion of NH3 and CO2 to urea is exothermic, with the reaction heat from the first reaction driving the second. The conditions that favor urea formation (high temperature) have an unfavorable effect on the carbamate formation equilibrium. The process conditions are a compromise: the ill-effect on the first reaction of the high temperature (around 190 °C (374 °F)) needed for the second is compensated for by conducting the process under high pressure (1.4–1.75 MPa (203–254 psi)), which favors the first reaction. Although it is necessary to compress gaseous carbon dioxide to this pressure, the ammonia is available from the ammonia production plant in liquid form, which can be pumped into the system much more economically. To allow the slow urea formation reaction time to reach equilibrium, a large reaction space is needed, so the synthesis reactor in a large urea plant tends to be a massive pressure vessel.
== Human genes == Human genes encoding enzymes with procollagen galactosyltransferase activity include: Human genes encoding enzymes with procollagen galactosyltransferase activity (EC 2.4.1.50) include:
Hahn published his results in the Proceedings of the Royal Society on 24 May 1905. It was the first of more than 250 scientific publications in the field of radiochemistry. At the end of his time in London, Ramsay asked Hahn about his plans for the future, and Hahn told him about the job offer from Kalle & Co. Ramsay told him radiochemistry had a bright future, and that someone who had discovered a new radioactive element should go to the University of Berlin. Ramsay wrote to Emil Fischer, the head of the chemistry institute there, who replied that Hahn could work in his laboratory, but could not be a Privatdozent because radiochemistry was not taught there. At this point, Hahn decided that he first needed to know more about the subject, so he wrote to the leading expert on the field, Ernest Rutherford. Rutherford agreed to take Hahn on as an assistant, and Hahn's parents undertook to pay Hahn's expenses. From September 1905 until mid-1906, Hahn worked with Rutherford's group in the basement of the Macdonald Physics Building at McGill University in Montreal. There was some scepticism about the existence of radiothorium, which Bertram Boltwood memorably described as a compound of thorium X and stupidity. Boltwood was soon convinced that it did exist, although he and Hahn differed on what its half-life was. William Henry Bragg and Richard Kleeman had noted that the alpha particles emitted from radioactive substances always had the same energy, providing a second way of identifying them, so Hahn set about measuring the alpha particle emissions of radiothorium.
=== Part two === The next evening, James, Cordelia and Matthew accompany Anna to Hell Ruelle, where Hypatia is hosting a party. Lucie, Christopher and Thomas spy on the Enclave meeting and find out that Oliver, Barbara's ex-fiancee had died as well, seemingly due to the fact that Barbara had scratched him before her death. This shocked the entire Enclave as demon poison had never been contagious before, and London is placed immediately under quarantine. In Hell Ruelle, Anna seduces Hypatia and Cordelia performs in front of the gathering. James and Matthew are impressed, however they notice Charles entering the club. Matthew pushes the couple away and they hide in The Whispering Room, where James and Cordelia kiss passionately. The next morning the Merry Thieves, Lucie, and Cordelia take advantage of the fact that Will and Tessa are gone for day-patrols, an added precaution by the Clave, and empty the Pyxis by letting out a Palpis demon named Agliarept, so that they may use it to trap the Mandikhor. They kill the demon before he could sway them. Since they performed it in the Sanctuary, Magnus walks in on them inquiring about their actions. They explain to him, their plans of ridding the shadow world of the demon and Cordelia implores Magnus to help them by casting an illusion over Tower Bridge, to protect and distract the mundanes. Magnus agrees. While they are going towards Tower Bridge, Magnus disproves James' theory of his grandfather being Belphegor.
It can also antagonize or diminish the HTR induced by LSD. Hence, (+)-JRT may be less psychedelic than LSD in humans. LSD and (+)-JRT are of similar potency in producing the HTR, with a maximal HTR being achieved at a dose of 0.2 mg/kg for both drugs. (+)-JRT does not affect locomotor activity and does not produce any serotonin behavioral syndrome-type effects. It has been found to inhibit dextroamphetamine-induced hyperlocomotion in female but not male mice, to not exacerbate phencyclidine (PCP)-induced hyperlocomotion, to not worsen dizocilpine (MK-801)-induced prepulse inhibition (PPI), and to not induce PPI deficits itself. Some of these findings are in contrast to results with LSD, and are suggestive that (+)-JRT lacks psychotic-like effects and may have antipsychotic potential. In addition to its other effects, (+)-JRT has been reported to increase neuroplasticity and hence to act as a psychoplastogen, to produce antidepressant-like effects, and to promote cognitive flexibility. It was equivalent with LSD in terms of producing psychoplastogenic effects.
Sources: en.wikipedia.org
Johnny Rep, former Ajax player, claimed that "everyone was on something". He recounted injections for everyone on 1 November 1979, ahead of a match of his team, Saint-Etienne, against PSV Eindhoven. Pierre Poty, who was physician of the club at that time, also revealed that he worked with uppers and reasoned it with the fantastic effects. Fritz Kessel, also physician, worked for the Dutch national side for 30 years and revealed that drugs were common in the 1974 and 1978 FIFA World Cups. He said that to Guido Derksen, writer of Voetbal Mysteries, who wrote that players "consumed tons of amphetamines." An investigative commission of sports medicine in Freiburg claims that in the late 1970s and in the 1980s Stuttgart and Freiburg football clubs were operating with Anabolika. VfB Stuttgart reordered Anabolika at least once. In 1987, Toni Schumacher wrote about a long-running tradition of doping in the Bundesliga, claiming that lots of players were taking Captagon. He himself experimented with it and the effects were: Increased aggression, lower pain threshold, increased focus, confidence and endurance. The by effect was sleeping problems. In Köln he was chauffeuring his colleagues to the doctor who gave them pills and injections, presumably anabolics and stimulants. In the national team he mentioned a "walking chemist" and hormone use. Despite being supported by Paul Breitner he had to leave Köln after 544 games.
During the visit to the archives, Xi said that "over the past 250 years, the American people have pursued the American Dream and built a prosperous country and a beautiful home on the North American continent" while "Chinese people, inheriting 5,000 years of Chinese civilization, have continued to make new achievements on the new journey toward realizing the Chinese Dream of the great rejuvenation of the Chinese nation". He said while "China and the United States have different histories and cultures, social systems and development paths", the "people of the two countries share the same aspiration for a better life despite the differences". Trump told reporters that "We’re just comparing. Ours goes 250 years. Which is great, and we’re proud of. Theirs goes 6,000 years. So there’s a little difference between 6,000 and 250. But we’re very proud of our 250." Before the visit finished, Trump gifted Xi a photo album of the trip. Afterwards, Xi and Peng left for Joint Base Andrews for their red carpet departure, with representatives of overseas Chinese and international students waving the Chinese and American flags on the road to on way to the airport. Senior US government officials saw them off at the airport, and a 21-gun salute was fired. They then onboarded a plane bound for Beijing, concluding the state visit. They returned to China on the afternoon of September 26.
=== Designation process === The NIH funds cancer centers through a P30 Cancer Center Support Grant (CCSG) mechanism. To be eligible to apply, a cancer center must receive at least $10 million in cancer research funding annually. Preparation for these grant applications can be extensive. The most recent grant application prepared by MD Anderson Cancer Center took 24 months to prepare and ran to 2,963 pages. Cancer centers must renew their status with the NIH every 5 years. The NCI considers the certain characteristics essential to a cancer center, and requires that applications address the institutions' resources in the areas of: Physical Space, Organizational Capabilities, Transdisciplinary Collaboration and Coordination, Cancer Focus, Institutional Commitment, Center Director. Independent or freestanding cancer centers are entities unto themselves and are not considered to be part of a larger institution or university. The center’s administration controls all space, appointments and budgets. These institutions may have university affiliations, but they remain administratively and financially distinct. The NCI also supports Consortium Centers, wherein scientists and clinicians from multiple institutions enter into formal agreements to expand cancer research programs. Importantly, Consortium Partners are not themselves considered NCI-designated. The NCI has strict guidelines on how Consortium Partners can refer to their relationship with their parent Consortium Center.
== Amino acids == Amino acids contain both amino and carboxylic acid functional groups. (In biochemistry, the term amino acid is used when referring to those amino acids in which the amino and carboxylate functionalities are attached to the same carbon, plus proline which is not actually an amino acid). Modified amino acids are sometimes observed in proteins; this is usually the result of enzymatic modification after translation (protein synthesis). For example, phosphorylation of serine by kinases and dephosphorylation by phosphatases is an important control mechanism in the cell cycle. Only two amino acids other than the standard twenty are known to be incorporated into proteins during translation, in certain organisms:
Abnormal facial characteristics, consisting of pronounced eyes which are spaced far apart (hypertelorism), a high forehead, a compressed bridge of the nose or saddle nose, and a small lower jaw and chin (micrognathia), are also observed in the majority of cases. Those affected by PD can also suffer intellectual disabilities (approx. 75% of recorded cases do) ranging from mild to severe – mental development during childhood may therefore progress more slowly.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.